Tectonic Therapeutic Q1 net loss $25.2M; TX45 APEX Phase 2 enrollment near complete

Tectonic Therapeutic, Inc.

2026-Q1 EPS reported -$1.34

Net loss $25.2M in Q1 2026 vs. $15.9M in Q1 2025; R&D expense $20.9M (up $7.9M YoY).
Cash $236.9M as of Mar 31, 2026, providing runway into Q4 2028.
TX45 APEX Phase 2 in PH-HFpEF enrollment nearing completion; topline data expected late Q4 2026/early Q1 2027.
TX2100 Phase 1a in HHT ongoing; topline results expected by end of Q3 2026.
Appointed François Nader as Board Chair and Jessica Chutter as independent director.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Tectonic Therapeutic, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended March 31, 2026 and provided a general business update.

View on SEC.gov

Browse all earnings releases →

Tectonic Therapeutic, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-212069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.